Innovative Drug Discovery Center Thrives in South Africa
The Holistic Drug Discovery and Development Centre aims to tackle significant health challenges in Africa. Founded by Kelly Chibale, it stands as a beacon of hope for drug discovery on the continent.
Kelly Chibale established the Holistic Drug Discovery and Development Centre (H3D) at the University of Cape Town, South Africa, equipped to develop treatments for some of the world's most challenging diseases.
Chibale likens the search for new drugs to a fairy-tale quest that requires time and perseverance. "It doesn't mean that there aren't surprises or miracles," he notes, emphasizing the need for patience in drug discovery, where the goal is to find effective treatments for diseases such as malaria and tuberculosis.
H3D is distinguished as one of the few drug discovery facilities in Africa, a region often overlooked in the global pharmaceutical landscape. Chibale, a Zambian chemist, believes that having such a center is essential to address the health issues that disproportionately affect the continent.
Chibale's passion for chemistry began during his studies when he became fascinated with molecules and their transformations. He describes his relationship with organic chemistry as a love affair, expressing joy in the beauty of molecular structures.
His academic journey took him to the UK and the US, where he recognized the extensive drug discovery pipelines in wealthier nations. Chibale observed the vast resources and manpower dedicated to pharmaceutical research, in stark contrast to the limited capabilities available in Africa.
Upon completing his time in California, Chibale was drawn back to Africa by an opportunity at the University of Cape Town. He felt a spiritual calling to inspire others and demonstrate that world-class research could emerge from Africa.
Chibale accepted the position in 1996 and later founded H3D in 2010, believing that valuable research would attract attention and resources regardless of its geographic origin.
The H3D facility occupies a significant portion of the seventh floor of the chemistry building at the university. Chibale leads a team that utilizes advanced equipment and techniques to search for new medicines targeting prevalent diseases such as malaria and tuberculosis.
The research approach involves screening vast libraries of molecules to identify candidates that can effectively target pathogens without harming human cells. Chibale's team focuses on optimizing these promising compounds, aiming to develop effective treatments.
One notable success from the center was a malaria drug that entered clinical trials, marking a significant milestone as the first Africa-led project to achieve this stage of drug development. However, safety concerns in preclinical studies halted further testing.
Chibale's mission is to enhance health outcomes in Africa while retaining local talent, countering the trend of scientists leaving the continent for opportunities abroad. He emphasizes the importance of building capacity within Africa to nurture and develop its scientific workforce.
The H3D Centre currently employs over 75 individuals, including Mathew Njoroge, a scientist from Kenya, who expresses optimism about the future of drug discovery in Africa. Njoroge's role involves determining appropriate drug dosages for patients, a critical aspect of ensuring the efficacy and safety of new treatments.
Recognizing Africa's genetic diversity, Chibale and his team strive to ensure that drug testing considers the unique characteristics of various populations. Mwila Mulubwa, a drug scientist at the center, highlights the need for tailored approaches to drug metabolism, given the continent's diverse genetic makeup.